ClinicalTrials.gg
CompletedNCT00418938Updated Oct 17, 2018Results posted

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

A Phase 2 interventional study of Panitumumab and Bevacizumab in Cancer, Colon Cancer and Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Primary conditionColorectal NeoplasmsRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colorectal Neoplasms
Why
  1. The study's listed conditions name Colorectal Neoplasms, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
266
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
17th of 88
266 · median 70
Started
2006
with 5 others
Phase 2
60 of 90
3 open now
Registered
15th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 17th largest by enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2006, is one of 60 in phase 2, and was the 15th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed first-line oxaliplatin-based chemotherapy (with at least 4 doses of oxaliplatin-based chemotherapy) with at least 4 doses of bevacizumab (failure is defined as toxicity due to oxaliplatin-based chemotherapy or progression of disease on first-line treatment) will be randomized in a 1:1 ratio to receive either a once-every-two-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg or a Q2W FOLFIRI regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and institutional standard of care).

Read the detailed description

This phase 2, multicenter, open-label, randomized, two-arm study was designed to estimate the treatment effect of panitumumab in combination with FOLFIRI compared to bevacizumab in combination with FOLFIRI in subjects with metastatic colorectal cancer (mCRC) who had failed first-line therapy with at least 4 doses of oxaliplatin-based chemotherapy and bevacizumab. After data became available demonstrating that the treatment effect of antiepidermal growth factor receptor (EGFR) agents was limited to patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) mCRC, the study was amended to enroll only subjects with wild-type KRAS tumors. Eligible subjects were randomized in a 1:1 ratio to receive panitumumab 6 mg/kg plus FOLFIRI once every 2 weeks (Q2W) or bevacizumab 5 mg/kg or 10 mg/kg plus FOLFIRI Q2W. Randomization was stratified by the reason for first-line treatment failure (progression vs toxicity) and by intended bevacizumab dose (5 mg/kg vs 10 mg/kg). The intended bevacizumab doses were ascertained from sites at the time of site initiation. Subjects were treated with all or any components of second-line treatment until the occurrence of unacceptable adverse events, disease progression, death, loss to follow up, or study withdrawal by the subject, investigator, or sponsor. Tumor response was evaluated by blinded central radiology review per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 and by the investigator using either modified RECIST version 1.0 or clinical assessment. After subjects permanently discontinued all components of second-line treatment, they were to undergo a safety follow-up assessment 30 (± 7) days after the last dose. Subjects ending second-line treatment before disease progression were followed for PFS (radiographic disease assessment) every 12 weeks (± 14 days) from the safety follow-up visit until disease progression, initiation of a new therapy for mCRC, or until approximately 100 PFS events were observed in subjects with wild-type KRAS tumors. Subjects were also followed for survival every 12 weeks (± 14 days) from the safety follow-up assessment until approximately 100 PFS events were observed in subjects with wild-type KRAS tumors.

03

Conditions studied

  • Cancer
  • Colon Cancer
  • Colorectal Cancer
  • Metastatic Cancer
  • Rectal Cancer
  • Metastatic Colorectal Cancer

Keywords

  • EGFR
  • FOLFIRI
  • 2nd Line Therapy
  • 2nd Line mCRC Therapy
  • mCRC
  • Irinotecan
  • panitumumab
  • bevacizumab
04

In context

Colorectal Neoplasms Reclassified

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

This study's enrollment of 266 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Compared within Colorectal Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of adenocarcinoma of the colon or rectum that cannot, in the opinion of the investigator, be cured by surgical resection at the time of randomization
  • Wild-type KRAS expressing mCRC from the primary tumor or metastasis.
  • Failure of prior oxaliplatin-based chemotherapy with bevacizumab (at least four therapeutic doses of oxaliplatin-based chemotherapy and bevacizumab) for mCRC.
  • At least one uni-dimensionally per modified criteria.
  • Cooperative Oncology Group () performance status of 0 or 1
  • Man or woman 18 years of age or older
  • Hematology, chemistry, coagution, metabolic functions within normal or protocol-defined limits

Exclusion criteria

Exclusion Criteria

  • Previous irinotecan, anti-EGFr therapy (eg, cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) or vaccine for the treatment of mCRC
  • Radiotherapy ≤ 14 days before randomization
  • Evidence of central nervous system (CNS)
  • Unresolved toxicities from prior anti-cancer therapy that, in the opinion of the investigator, precludes subject from participation
  • History of other invasive primary cancer, except:
  • Curatively resected or treated non-melanomatous skin cancer
  • Curatively treated cervical carcinoma in situ
  • Other primary solid tumor treated curatively and no treatment administered ≤ 2 years before randomization and, in the investigator's opinion, it is unlikely that there will be a recurrence ≤ 2 years post randomization

Medications

  • C hronic daily treatment (as determined by the investigator) with aspirin (> 325 mg/day) or non steroidal anti inflammatory agents known to inhibit function
  • Infection requiring a course of systemic anti-infectives that was completed ≤ 14 days before randomization (exception can be made at the judgment of the investigator for oral treatment of an uncomplicated urinary tract infection [UTI])
  • Subjects concurrently receiving any agent or therapy ≤ 30 days before randomization

General:

  • Significant cardiovascular risk as defined by the protocol
  • History of peripheral arterial ischemia ≤ 24 weeks before randomization (subjects with brief, reversible, exercise-induced claudication are eligible)
  • History of visceral arterial ischemia ≤ 24 weeks before randomization
  • Significant bleeding risk:
  • Major surgical procedure, open , or significant traumatic injury ≤ 28 days before randomization
  • Anticipation of need for major surgical procedures during the course of the study
  • C ore biopsy or other minor procedure, excluding placement of a vascular access device ≤ 7 days before randomization
  • A ny significant bleeding that is not related to the primary colon tumor ≤ 24 weeks before randomization
  • P re-existing bleeding diathesis or coagulopathy with the exception of well-controlled chronic anticoagulation therapy
  • Serious or non-healing wounds, skin ulcers, or unhealed bone fractures
  • Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled gastrointestinal ulcer ≤ 28 days before randomization
  • History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest x-ray (CXR) or computed tomography (CT) scan
  • ascites
  • Subjects known to be (HIV) positive or known to have chronic or active or C infection
  • Men and women of (women who are \< 52 weeks, not surgically sterilized, or not abstinent) who do not consent to use adequate (according to institutional standard of care) during the course of the study and after the last date of receiving treatment (24 weeks for women, 4 weeks for men)
  • Women who test positive for serum or urine pregnancy test ≤ 72 hours before randomization or are breast-feeding
  • Subjects allergic to any component that is part of the treatment regimen
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
266 participants (actual)

Study arms

  • Experimental
    Arm A

    FOLFIRI + Panitumumab

    Drug: Panitumumab · Drug: Leucovorin · Drug: Irinotecan · Drug: 5-Fluorouracil

  • Experimental
    Arm B

    FOLFIRI + Bevacizumab

    Drug: Bevacizumab · Drug: Leucovorin · Drug: Irinotecan · Drug: 5-Fluorouracil

Interventions

  • 6mg/kg IV

  • Either 5mg/kg OR 10mg/kg IV

  • 400mg/m\^2 IV (in the vein)

  • 180mg/m\^2 IV (in the vein)

  • 400mg/m\^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m\^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m\^2 thereafter if no significant side effects

07

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later).

    Time frame: From randomization up to 65 months.

Secondary outcomes

  1. Overall Survival

    Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date.

    Time frame: From randomization up to 65 months.

  2. Objective Response Rate

    Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment.

    Time frame: From randomization up to 65 months.

  3. Time to Response

    Time to response is defined as time from the date of randomization to the date of first confirmed objective response

    Time frame: From randomization up to 65 months.

  4. Time to Progression

    Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment).

    Time frame: From randomization up to 65 months.

  5. Disease Control

    Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy.

    Time frame: From randomization up to 65 months.

  6. Duration of Response

    Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment).

    Time frame: From randomization up to 65 months.

08

Results

Posted Mar 28, 2014

Participant flow

Participant flow — Overall Study
MilestonePanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Started133131
Completed109108
Not completed2423
Withdrew: Reimbursement10
Withdrew: Administrative decision33
Withdrew: Withdrawal by subject1615
Withdrew: Lost to follow-up13
Withdrew: Adverse event11
Withdrew: On-going11
Withdrew: Ineligibility determined10

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later).

Time frame:
From randomization up to 65 months.
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS (n=91,91)7.7 (5.7 to 11.8)9.2 (7.8 to 10.6)
Mutant KRAS (n=36,32)3.7 (2.7 to 5.5)6.4 (3.5 to 17.1)
SecondaryOverall Survival

Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date.

Time frame:
From randomization up to 65 months.
Reported as:
Median · months
Overall Survival
monthsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS (n=91,91)18.0 (13.5 to 21.7)21.4 (16.5 to 24.6)
Mutant KRAS (n=36,32)8.7 (6.1 to 14.5)13.5 (9.1 to 14.3)
SecondaryObjective Response Rate

Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment.

Time frame:
From randomization up to 65 months.
Reported as:
Number · % of patients
Objective Response Rate
% of patientsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS (n=91,91)32.18 (22.56 to 43.06)19.28 (11.44 to 29.41)
Mutant KRAS (n=36,32)11.76 (3.30 to 27.45)3.33 (0.08 to 17.22)
SecondaryTime to Response

Time to response is defined as time from the date of randomization to the date of first confirmed objective response

Time frame:
From randomization up to 65 months.
Reported as:
Median · months
Time to Response
monthsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS (n=91,91)2.1 ± 2.23.7 ± 1.2
Mutant KRAS (n=36,32)2.2 ± 0.21.8 ± NA
SecondaryTime to Progression

Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment).

Time frame:
From randomization up to 65 months.
Reported as:
Median · months
Time to Progression
monthsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS11.1 (7.5 to 13.2)9.4 (8.2 to 11.9)
Mutant KRAS4.5 (3.0 to 12.0)7.4 (5.7 to 19.2)
SecondaryDisease Control

Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy.

Time frame:
From randomization up to 65 months.
Reported as:
Number · % of participants
Disease Control
% of participantsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS (n=91,91)72.41 (61.79 to 81.46)79.52 (69.24 to 87.59)
Mutant KRAS (n=36,32)52.94 (35.13 to 70.22)66.67 (47.19 to 82.71)
SecondaryDuration of Response

Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment).

Time frame:
From randomization up to 65 months.
Reported as:
Median · months
Duration of Response
monthsPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
Wild-type KRAS (n=91,91)12.7 (7.9 to 19.1)8.9 (6.5 to 13.6)
Mutant KRAS (n=36,32)10.2 (9.8 to 13.5)15.2 (NA to NA)

Adverse events

Collected over The median reporting period was since randomization date to 65 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panitumumab Plus FOLFIRI—61/133 (45.9%)133/133 (100%)
Bevacizumab Plus FOLFIRI—39/131 (29.8%)129/131 (98.5%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
DiarrhoeaGastrointestinal disorders9/1334/131
Pulmonary embolismRespiratory, thoracic and mediastinal disorders8/1331/131
DehydrationMetabolism and nutrition disorders7/1336/131
VomitingGastrointestinal disorders5/1333/131
Abdominal painGastrointestinal disorders4/1334/131
Small intestinal obstructionGastrointestinal disorders4/1333/131
NeutropeniaBlood and lymphatic system disorders2/1333/131
NauseaGastrointestinal disorders2/1333/131
Urinary tract infectionInfections and infestations3/1333/131
SepsisInfections and infestations3/1332/131
Most frequent other events
Showing 10 of 66
Most frequent other events
EventPanitumumab Plus FOLFIRIBevacizumab Plus FOLFIRI
DiarrhoeaGastrointestinal disorders93/13387/131
NauseaGastrointestinal disorders69/13388/131
FatigueGeneral disorders76/13380/131
RashSkin and subcutaneous tissue disorders80/1339/131
NeutropeniaBlood and lymphatic system disorders44/13353/131
VomitingGastrointestinal disorders47/13347/131
HypomagnesaemiaMetabolism and nutrition disorders47/13314/131
ConstipationGastrointestinal disorders43/13334/131
HypokalaemiaMetabolism and nutrition disorders42/13323/131
Decreased appetiteMetabolism and nutrition disorders38/13341/131

Baseline characteristics

Age, Continuous
Age, Continuous(years)Panitumumab Plus FOLFIRIBevacizumab Plus FOLFIRITotal
Mean59.9 ± 11.659.1 ± 9.959.5 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Panitumumab Plus FOLFIRIBevacizumab Plus FOLFIRITotal
Female464692
Male8785172
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Panitumumab Plus FOLFIRIBevacizumab Plus FOLFIRITotal
White or Caucasian10295197
Black or African American211839
Hispanic or Latino5914
Asian4812
American Indian or Alaska Native101
Other011
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants)Panitumumab Plus FOLFIRIBevacizumab Plus FOLFIRITotal
0 (Fully active)7470144
1 (Restricted in physically strenuous activity)5861119
Missing101
Primary tumor diagnosis
Primary tumor diagnosis(Participants)Panitumumab Plus FOLFIRIBevacizumab Plus FOLFIRITotal
Colon10291193
Rectum314071
Number of metastatic organs
Number of metastatic organs(Participants)Panitumumab Plus FOLFIRIBevacizumab Plus FOLFIRITotal
14961110
2394281
>=3442872
Missing101
09

Study locations

No study locations are listed for this record.

10

References and documents

Publications

  • Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Jun;14(2):72-80. doi: 10.1016/j.clcc.2014.12.009. Epub 2015 Jan 8. PubMed 25982297 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2006 to primary completion in May 2012, 66 months.

Results were first posted in Mar 2014, 1 year 10 months after primary completion. A results delay was requested in Jul 2010.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 66 months is above that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2007
First posted
Jan 5, 2007
StartActual
Nov 1, 2006
Primary completionActual
May 10, 2012
CompletionActual
Apr 1, 2013
Results delay requested
Jul 20, 2010
Results first posted
Mar 28, 2014
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00418938
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jan 5, 2007
Start date
Nov 1, 2006
Primary completion
May 10, 2012
Completion
Apr 1, 2013
Results posted
Mar 28, 2014
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Panitumumab · Bevacizumab

Start the discussion